Procyrion, Inc. is a medical device company focused on developing the world's first catheter-deployed heart pump, known as the Aortix system. This innovative technology is designed to assist heart function and improve clinical outcomes for patients with heart failure.

Procyrion

Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system.

Aortix™ is currently in the research and development phase and is not available for sale in any country.
(Caution: investigational device. Limited by federal law to investigational use.)

Scientific Health Development Partners

Aquinas

Jefferson River Capital

BlueBird Merchant Ventures

Fannin Innovation Studio

Houston Angel Network

Procyrion, Inc.

Our DRAIN-HF trial evaluating the #Aortix pump for acute decompensated #heartfailure patients is well underway. Congrats to Henry Ford Hospital and John Muir Hospital for enrolling multiple patients in this important study! 

#clinicaltrials #cardiorenalsyndrome #diureticresistance #innovation

Another DRAIN-HF site begins patient enrollment! Congrats to Dr. Miguel Alvarez Villela and the Northwell Health Lenox Hill team on enrolling your first patient in this groundbreaking trial for #heartfailure patients. 
 
#clinicaltrials #cardiorenalsyndrome #diureticresistance #Aortix #innovation

BREAKING NEWS: We are proud to be recognized as a #Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix technology and the potential it has to change the way patients with acute decompensated #heartfailure and cardiorenal syndrome are treated.

https://lnkd.in/gR47YYhU

First DRAIN-HF enrollment in the Bay Area! Congrats to Dr. Andrew Dublin, Dr. Wayland Lim and the team at John Muir Health on enrolling your first patient in this groundbreaking trial of Aortix for #heartfailure patients.  
#clinicaltrials #cardiorenalsyndrome #diureticresistance

Our President & CEO Eric Fain had the opportunity to connect with Tom Salemi, host of the DeviceTalks podcast, earlier this week. Eric details how our recent $57.7 million round will help us in our quest to make the company's innovative Aortix technology available to physicians and patients with acute decompensated heart failure and cardiorenal syndrome. 
https://bit.ly/3SvX7HD

Metric
Company Name	Procyrion
Symbol
MSH ID	COM:PROCYRION
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage
Employee Count	27
Website	procyrion.com
LinkedIn	procyrion
Founders

Metric
Market Cap	308.64M
Enterprise Value
Monthly Web Traffic	218
Web Traffic Growth	-0.93
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	40.44
28-Day Growth Score	13.94
90-Day Growth Score	11.94
365-Day Growth Score	11.64

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PROCYRION

Procyrion

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue